Aether Industries Limited, a specialty chemical manufacturer that focuses on advanced intermediates and specialty chemicals announced the execution of a contract/exclusive manufacturing agreement with Chemoxy International Limited, a wholly owned subsidiary of the SEQENS Group (Seqens).
The SEQENS Group, headquartered in France, is into health, personal care, and specialty ingredients, operating 16 production sites and nine R&D centres worldwide, with an annual revenue of €1.1 billion. The strategic partnership solidifies Aether’s position as a prominent player in the specialty chemicals sector.
As per the press release, under this take-or-pay contract, Aether will exclusively produce a series of natural bio-based products for SEQENS Group. The contract covers an initial period of three years, with production expected to commence within the next 10 months, targeting a volume of 100+ MT per year.
Dr. Aman Desai, Whole-time Director, Ather Industries Ltd said, “The manufacturing process, which involves advanced continuous reaction technology, was collaboratively developed by Aether and SEQENS Group over the past three years. This venture is a significant milestone for Aether’s Renewables and Sustainability business segment, further establishing Aether as a leading India-based specialty chemical manufacturer and a provider of sustainable and carbon-neutral chemistry solutions across the industry spectrum around the world”.
